Cilastatin / Imipenem / Relebactam Dosage

Medically reviewed by Drugs.com. Last updated on Mar 4, 2024.

Usual Adult Dose for Nosocomial Pneumonia

1.25 g IV every 6 hours for 4 to 14 days

Uses: For the treatment of patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia due to susceptible Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, K oxytoca, K pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens

Usual Adult Dose for Pyelonephritis

1.25 g IV every 6 hours for 4 to 14 days

Comments:

• Approval of this indication based on limited clinical safety and efficacy data for this drug.

Use: In patients with limited or no alternative treatment options, for the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E cloacae, E coli, K aerogenes, K pneumoniae, and P aeruginosa

Usual Adult Dose for Urinary Tract Infection

1.25 g IV every 6 hours for 4 to 14 days

Comments:

• Approval of this indication based on limited clinical safety and efficacy data for this drug.

Use: In patients with limited or no alternative treatment options, for the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E cloacae, E coli, K aerogenes, K pneumoniae, and P aeruginosa

Usual Adult Dose for Intraabdominal Infection

1.25 g IV every 6 hours for 4 to 14 days

Comments:

• Approval of this indication based on limited clinical safety and efficacy data for this drug.

Use: In patients with limited or no alternative treatment options, for the treatment of complicated intraabdominal infections due to susceptible Bacteroides caccae, B fragilis, B ovatus, B stercoris, B thetaiotaomicron, B uniformis, B vulgatus, Citrobacter freundii, E cloacae, E coli, Fusobacterium nucleatum, K aerogenes, K oxytoca, K pneumoniae, Parabacteroides distasonis, and P aeruginosa

Renal Dose Adjustments

Estimated CrCl 60 to 89 mL/min: 1 g IV every 6 hours
Estimated CrCl 30 to 59 mL/min: 750 mg IV every 6 hours
Estimated CrCl 15 to 29 mL/min: 500 mg IV every 6 hours
Estimated CrCl less than 15 mL/min: Not recommended unless hemodialysis started within 48 hours.

Comments:

• CrCl should be monitored in patients with fluctuating renal function.
• CrCl calculated using Cockcroft-Gault formula.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
History of known severe hypersensitivity (severe systemic allergic reaction [e.g., anaphylaxis]) to an active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

ESRD on hemodialysis: 500 mg IV every 6 hours
Peritoneal dialysis: Data not available

Comments:

• Administration should be timed to follow hemodialysis.
• For patients maintained on hemodialysis, this drug should be administered after hemodialysis and at intervals timed from the end of that hemodialysis session.
• The active components are removed from circulation during hemodialysis.

Other Comments

1.25 g imipenem/cilastatin/relebactam contains 500 mg imipenem, 500 mg cilastatin, and 250 mg relebactam
1 g imipenem/cilastatin/relebactam contains 400 mg imipenem, 400 mg cilastatin, and 200 mg relebactam
750 mg imipenem/cilastatin/relebactam contains 300 mg imipenem, 300 mg cilastatin, and 150 mg relebactam
500 mg imipenem/cilastatin/relebactam contains 200 mg imipenem, 200 mg cilastatin, and 100 mg relebactam

Administration advice:

• Administer by IV infusion over 30 minutes.
• Do not coadminister this drug through the same IV line (or cannula) with drug products other than those listed below as compatible injectable drugs; consult the respective manufacturer product information of coadministered drug(s) to confirm compatibility of simultaneous coadministration.

Storage requirements:

• Before constitution: Store vials at 20C to 25C (68F to 77F), excursions permitted between 15C to 30C (59F to 86F); keep vials in the carton.
• After constitution and further dilution in infusion bag: Solution maintains satisfactory potency for at least 2 hours at room temperature (up to 30C) or for at least 24 hours refrigerated at 2C to 8C (36F to 46F); do not freeze solution.

Reconstitution/preparation techniques:

• This drug must be constituted and further diluted before IV infusion.
• The manufacturer product information should be consulted.

IV compatibility:

• Compatible Diluents: 0.9% Sodium Chloride Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose Injection, USP plus 0.9% Sodium Chloride Injection, USP; 5% Dextrose Injection, USP plus 0.45% Sodium Chloride Injection, USP; 5% Dextrose Injection, USP plus 0.225% Sodium Chloride Injection, USP
• Compatible Injectable Drugs (for use with 5% Dextrose USP or 0.9% Sodium Chloride USP Injection as diluents): Dexmedetomidine, dopamine, epinephrine, fentanyl, heparin, midazolam, norepinephrine, phenylephrine
• No compatibility data are available for other drug products.
• Incompatible (physically): Propofol in 5% Dextrose, USP or 0.9% Sodium Chloride, USP

General:

• Duration of therapy should be guided by severity and location of infection and patient clinical response.
• To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria.
• Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.

Monitoring:

• Renal: CrCl in patients with fluctuating renal function; renal function in elderly patients

Patient advice:

• Avoid missing doses and complete the entire course of therapy.
• Contact healthcare provider if severe watery or bloody diarrhea develops.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer